DV
Dividend Vision

ABOS — Acumen Pharmaceuticals Inc

Acumen Pharmaceuticals Inc (ABOS)

Total return is -86.7% over the past 5.1 years, 179.7 points behind SPY at 93.0%. Its deepest 1-year drawdown was 37.4%.

ABOS is an equity fund focused on a single pharmaceutical company. The fund holds stock in Acumen Pharmaceuticals and does not currently offer dividend distributions, making it unsuitable for income-focused investors. This concentrated holding appeals primarily to investors seeking direct exposure to a specific biotech company rather than broad diversification or yield generation.

ABOS key facts

Asset type
Stock
Asset class
Equity
Inception date
07/01/2021
Last close
$2.67
Market cap
$162,512,064
Average volume
526700.0
Beta
0.341
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.85